No medications are currently approved for the treatment of nonobstructive hypertrophic cardiomyopathy. Could a new drug from Imbria Pharmaceuticals be the first?
Imagers can now identify vulnerable plaques that were once very challenging to find. The next steps include improving the screening process and determining which lesions need to be treated right away.
TAVR may get more attention, but the Ross procedure has also gained significant momentum in recent years. Ismail El-Hamamsy, MD, PhD, detailed his own team's success with the complex procedure.
Mary E. Brunkow, PhD; Fred Ramsdell, PhD; and Shimon Sakaguchi, PhD, MD, will share the 2025 prize for research that has led to new treatments for autoimmune disease and cancer.
Ajay Kirtane, MD, director of the cardiac catheterization laboratories at NewYork-Presbyterian/Columbia University Irving Medical Center, explained the most recent clinical trial data on this topic.
New imaging data indicates that the effects of long COVID may begin to dwindle over time, offering hope for those suffering from the long-term ramifications of the virus.
Using risk model-based strategies to determine who should undergo low-dose CT lung cancer screening is more cost effective than current U.S. Preventive Services Task Force guidelines.
TAVR patients presenting with peripheral artery disease face significantly higher in-hospital risks, according to a new study published in Current Problems in Cardiology.
The data, published in Clinical Imaging, reveal that more than 20% of respondents have witnessed scientific fraud within their department and more than 85% reported the issue of publication bias.
